Changes of various RNA modifications in patients with HFpEF

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000040038

Enrollment

Unknown

Registered

2020-11-18

Start date

2020-11-14

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart failure with preserved ejection fraction

Interventions

HFpEF group:None

Control group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HFpEF patients who meet the diagnostic criteria of 2019 ESC-HFA.

Exclusion criteria

Exclusion criteria: 1. Being enrolled in other drug studies or enrolled in other drug studies within 30 days; 2. Severe abnormal liver function (ALT or AST more than 3 times the normal upper limit); 3. Glomerular filtration rate (eGFR) was less than 30ml / min / 1.73m2; 4. Cancer patients; 5. Pregnant or ready to give birth.

Design outcomes

Primary

Measure	Time frame
Changes in various RNA modifications in the blood;	—

Countries

China

Contacts

Public ContactJunbo Ge

??????????

jbge@zs-hospital.sh.cn+86 21 64041990

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026